Skip to main content

Designer Circular RNA as Protein Sponge for Cancer Therapy


Kurzfassung

The new circular RNA enables specific binding and inhibition of heterogeneous nuclear ribonucleoprotein L in cells and thus opens new therapeutic approaches for the treatment of pancreatic and other cancer types, where hnRNP L is deregulated.


Hintergrund

The new circular RNA is very stable, it can easily be transfected into cells. It is used to sponge and thereby inhibit selectively hnRNP L.


Bilder & Videos


Lösung

A new artificial circular RNA with an unusual ribonucleotide sequence was designed to bind and inhibit intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L). HnRNP L plays an essential role in the development of pancreatic and other cancer types.


Vorteile

  • Circular RNA is much more stable than the corresponding linear RNA.
  • Circular RNA can be designed to sponge RNA-binding proteins, thereby inhibiting the metabolic function of such proteins.
  • Circular RNA can easily be introduced into cells and has no adverse side effects.
  • A circular RNA was designed to bind hnRNP L with high specificity and affinity, inactivating this protein and thus opening up new therapy options for pancreatic and other cancer types, where hnRNP L is deregulated.

Anwendungsbereiche

The new circular RNA is useful in pancreatic and oral squamous cell cancer therapy, when hnRNP L is overexpressed, based on binding and inhibiting intracellular heterogeneous nuclear ribonucleoprotein L (hnRNP L).


Service

On behalf of its shareholder Justus-Liebig-Universität Giessen TransMIT GmbH is looking for cooperation partners or licensees for further development in Germany, Europe, US, and Asia.


TransMIT Gesellschaft für Technologietransfer mbH

Anouschka Ulherr
0641 946434
anouschka.ulherr@transmit.de

Adresse
Kerkrader Str. 3
35394 Gießen



Entwicklungsstand

Leitstruktur


Stichworte

Circular RNA, pancreatic cancer therapy, hnRNP L, heterogeneous nuclear ribonucleoprotein L, protein sponging, RNA-binding proteins, molecular medicine, oral squamous cell carcinoma therapy

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsführerin)

c/o TransMIT GmbH
Kerkrader Straße 3
D-35394 Gießen